Obermatt
See Similar Stocks →

Vera Therapeutics

NMQ:VERA · US92337R1014
BiotechnologySmall

360

44
Medium confidence — indicative
Profit price43
Owner Earnings Yield1
Dividend Yield1
Price/Sales50
Price/Book9
Return on Capital9
Cash Return on Capital17
Return on Equity16
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth4
Long-Term EPS Growth73
Reinvestment33
Price momentum50
Debt load38
Refinancing57
Debt Payback1
Liquidity56
Analyst ratings48
Opinion Changes50
Price Target Upside94
Market mood100
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Vera Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2016
Employees263
Websiteveratx.com
ISINUS92337R1014
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NephrologyImmunologyHematologyChronic DiseasesStem Cell TherapyBiotechnology

Description

Vera Therapeutics, Inc. operates as a late clinical-stage biotechnology company. The company focuses on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate,…

Analysis

Middle-of-the-road

Vera Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
22
2026

All-time high

36

Mar 2026

All-time low

22

Jun 2026

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
50
—
—
—
Price/Earnings
64
—
—
—
Price/Book
9
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
8
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Vera Therapeutics with its peers
Aurinia Pharmaceuticals
NMQ:AUPH
85
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nkarta
NSQ:NKTX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Jade Biosciences
NAQ:JBIO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Invivyd
NMQ:IVVD
40
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →